Navigation Links
Burrill Merchant Banking Advises Pfizer Inc. on Dermatology Portfolio Divestment

SAN FRANCISCO, July 14 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to Pfizer Inc. on its recently-completed divestment of three investigational compounds for dermatological conditions to Graceway Pharmaceuticals, LLC. Financial terms of the agreement were not disclosed.

The most advanced product is a novel Cholesterol-Aceyltransferase (ACAT) inhibitor currently in Phase 2 development for the treatment of oily skin and acne. An earlier-stage Stearoyl CoA Desaturase 1 (SCD1) Inhibitor targeting the same indication was also included in the transaction, as was an Activin-Like Kinase 5 (ALK-5) inhibitor currently in preclinical development for reducing scarring resulting from surgery or trauma.

Simultaneous with the out-licensing transaction, Pfizer and Graceway executed a Master Services and Supply Agreement under which Pfizer agreed to provide clinical and other development support for the three licensed compounds.

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies in identifying, negotiating and closing strategic transactions. Service lines include:

  • Mergers & Acquisitions
  • Strategic Partnering
  • Spin-Outs and Divestitures
  • Financing (Private Placements)
  • Advisory Services to define the role of transactions in achieving strategic objectives

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report, which tracks the progress of the global biotechnology industry and annual "State of the Industry" report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd annual report on the industry. The 470-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond. For more information, visit

SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Burrill & Company Announces Promotions
2. Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
3. Biotech Finishes on a High in August, Burrill Report Says
4. Retail Union Head Blasts Merchants Group for Opposition to Health Care Reform
5. Network Merchants, Inc (NMI) Founders Donate $50,000 to Schaumburgs Childrens Home & Aid
6. New York Merchants Protective Co. Renews CSAA Five Diamond Certification
7. New Certification Seal Identifies Merchants Committed to Fighting Identity Theft
8. Simon Property Group Selects New York Merchants Protective Co., Inc. for Fire-alarm Services
9. United Physicians, P.C. Selects National City, Now Part of PNC, for Physician Banking Program
10. Cord Blood Registry Supports Family Cord Blood Banking Act
11. BancTec Provides Thought Leadership at 7th Annual Medical Banking Institute
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: